NA Liver Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Description

List of Tables

The North America liver cancer diagnostics market is projected to register a substantial CAGR of 6.6% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation:

North America Liver Cancer Diagnostics Market, By Test Type (Imaging, Biopsy, Genomic Test, and Others), Cancer Stages (Stage 0, Stage I, Stage II, Stage III, and Stage IV), Cancer Type (Primary Liver Cancer and Secondary Liver Cancer), Product (Platform-Based Products, Instrument Based Products, Kits and Reagents, and Other Consumables), Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluorimmunoassay, Comparative Genomic Hybridization, Immunohistochemical, and Others), Application (Screening, Diagnostic and Predictive, Prognostic, and Research), Gender (Female and Male), End User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (U.S., Canada, and Mexico) - Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the North America liver cancer diagnostics market are:

Rise in prevalence and incidence of liver cancer in the world

Increase in awareness about the liver cancer diagnostics

Market Players:

Some of the major players operating in the North America liver cancer diagnostics market are:

F. Hoffmann-La Roche Ltd.

Koninklijke Philips N.V.

Thermo Fisher Scientific Inc.

Siemens Healthcare GmbH

Agilent Technologies, Inc.

Illumina, Inc.

QIAGEN

FUJIFILM Corporation

Sysmex Corporation AB

Scitex Pte Ltd. (Subsidiary of Danaher.)

Epigenomics AG

Tebubio

Fujirebio

Diagnostic Biosystems Inc.

Q-LINE BIOTECH PVT LTD.

MOLGEN

BIOCEPT, INC.

Boditech Med Inc.

Elabscience Biotechnology Inc.

Hipro Biotechnology Co., Ltd.

Altogen Biosystems

Tosoh India Pvt. Ltd.

ABK Biomedical Inc.

Diazyme Laboratories, Inc.

1 INTRODUCTION 55

1.1 OBJECTIVES OF THE STUDY 55
1.2 MARKET DEFINITION 55
1.3 OVERVIEW OF THE NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET 55
1.4 CURRENCY AND PRICING 57
1.5 LIMITATIONS 57
1.6 MARKETS COVERED 58

2 MARKET SEGMENTATION 61

2.1 MARKETS COVERED 61
2.2 GEOGRAPHICAL SCOPE 62
2.3 YEARS CONSIDERED FOR THE STUDY 63
2.4 DBMR TRIPOD DATA VALIDATION MODEL 64
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 67
2.6 MULTIVARIATE MODELLING 68
2.7 MARKET APPLICATION COVERAGE GRID 69
2.8 TEST TYPE LIFELINE CURVE 70
2.9 DBMR MARKET POSITION GRID 71
2.10 VENDOR SHARE ANALYSIS 72
2.11 SECONDARY SOURCES 73
2.12 ASSUMPTIONS 73

3 EXECUTIVE SUMMARY 74

4 PREMIUM INSIGHTS 77

4.1 PESTLE ANALYSIS 78
4.2 PORTER ANALYSIS 79
4.3 EPIDEMIOLOGY 80

5 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, REGULATIONS 81

6 INDUSTRY INSIGHTS 85

7 MARKET OVERVIEW 87

7.1 DRIVERS 89
- 7.1.1 UNMET NEED FOR NON-INVASIVE, ACCURATE, AND RELIABLE DIAGNOSTIC TESTS FOR EARLIER CANCER DETECTION 89
- 7.1.2 INCREASING EARLY DIAGNOSIS OF LIVER CANCER 90
- 7.1.3 INCREASING CASES OF LIVER CANCER 92
- 7.1.4 RISE IN DIAGNOSTIC PRODUCT APPROVALS 93
7.2 RESTRAINTS 95
- 7.2.1 BARRIERS TO LIVER CANCER DIAGNOSIS AND POOR PROGNOSIS 95
- 7.2.2 HIGH FALSE-POSITIVES AND POOR SENSITIVITY OF LIVER CANCER DIAGNOSIS 96
7.3 OPPORTUNITIES 96
- 7.3.1 INCREASING AWARENESS TOWARDS LIVER CANCER 96
- 7.3.2 GOVERNMENT INITIATIVES TOWARD LIVER CANCER DIAGNOSTICS 96
- 7.3.3 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE 97
7.4 CHALLENGES 98
- 7.4.1 STRICT REGULATIONS FOR THE APPROVAL OF LIVER CANCER DIAGNOSTIC PRODUCTS 98
- 7.4.2 LACK OF SKILLED AND CERTIFIED EXPERTISE 99

8 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 100

8.1 OVERVIEW 101
8.2 IMAGING TEST 104
- 8.2.1 MAGNETIC RESONANCE IMAGING (MRI) 105
  - 8.2.1.1 MR ANGIOGRAPHY (MRA) 105
  - 8.2.1.2 MR CHOLANGIOPANCREATOGRAPHY 106
- 8.2.2 COMPUTED TOMOGRAPHY 106
- 8.2.3 POSITRON EMISSION TOMOGRAPHY 106
- 8.2.4 ULTRASOUND 106
- 8.2.5 OTHERS 106
8.3 GENOMIC TEST 106
8.4 BIOPSY 107
- 8.4.1 FINE NEEDLE ASPIRATION BIOPSY 108
- 8.4.2 CORE NEEDLE BIOPSY 108
- 8.4.3 LAPAROSCOPY 108
8.5 OTHERS 109

9 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGE 110

9.1 OVERVIEW 111
9.2 STAGE III 114
9.3 STAGE II 115
9.4 STAGE IV 116
9.5 STAGE I 117
9.6 STAGE 0 118

10 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE 119

10.1 OVERVIEW 120
10.2 SECONDARY LIVER CANCER 123
- 10.2.1 HEMANGIOMA 124
- 10.2.2 HEPATIC ADENOMA 124
- 10.2.3 FOCAL NODULAR HYPERPLASIA 124
10.3 PRIMARY LIVER CANCER 124
- 10.3.1 HEPATOCELLULAR CARCINOMA (HCC) 125
- 10.3.2 INTRAHEPATIC CHOLANGIOCARCINOMA (BILE DUCT CANCER) 125
- 10.3.3 ANGIOSARCOMA HEMANGIOSARCOMA 126
- 10.3.4 HEPATOBLASTOMA 126

11 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT 127

11.1 OVERVIEW 128
11.2 PLATFORM BASED PRODUCTS 131
- 11.2.1 NEXT GENERATION SEQUENCING 132
- 11.2.2 MICROARRAYS 132
- 11.2.3 PCR 132
- 11.2.4 OTHERS 132
11.3 INSTRUMENT BASED PRODUCTS 132
- 11.3.1 IMAGING 133
- 11.3.2 BIOPSY 133
11.4 KITS AND REAGENTS 134
- 11.4.1 ELISA TEST KITS 135
- 11.4.2 CASSETTE TEST KITS 135
- 11.4.3 OTHERS 135
11.5 OTHER CONSUMABLES 135

12 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION 136

12.1 OVERVIEW 137
12.2 SCREENING 140
- 12.2.1 PLATFORM BASED PRODUCTS 141
- 12.2.2 INSTRUMENT BASED PRODUCTS 141
- 12.2.3 KITS AND REAGENTS 141
- 12.2.4 OTHER CONSUMABLES 141
12.3 DIAGNOSTIC AND PREDICTIVE 141
- 12.3.1 PLATFORM BASED PRODUCTS 142
- 12.3.2 INSTRUMENT BASED PRODUCTS 142
- 12.3.3 KITS AND REAGENTS 142
- 12.3.4 OTHER CONSUMABLES 143
12.4 PROGNOSTIC 143
- 12.4.1 PLATFORM BASED PRODUCTS 144
- 12.4.2 INSTRUMENT BASED PRODUCTS 144
- 12.4.3 KITS AND REAGENTS 144
- 12.4.4 OTHER CONSUMABLES 144
12.5 RESEARCH 144
- 12.5.1 PLATFORM BASED PRODUCTS 146
- 12.5.2 INSTRUMENT BASED PRODUCTS 146
- 12.5.3 KITS AND REAGENTS 146
- 12.5.4 OTHER CONSUMABLES 146

13 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY 147

13.1 OVERVIEW 148
13.2 FLUORESCENT IN SITU HYBRIDIZATION 151
13.3 NEXT GENERATION SEQUENCING 152
13.4 FLUORIMMUNOASSAY 153
13.5 COMPARATIVE GENOMIC HYBRIDIZATION 154
13.6 IMMUNOHISTOCHEMICAL 155
13.7 OTHERS 156

14 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY GENDER 157

14.1 OVERVIEW 158
14.2 MALE 161
14.3 FEMALE 162

15 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY END USER 163

15.1 OVERVIEW 164
15.2 HOSPITALS 167
15.3 DIAGNOSTIC CENTERS 168
15.4 CANCER RESEARCH CENTERS 169
15.5 AMBULATORY SURGICAL CENTERS 170
15.6 ACADEMIC INSTITUTES 171
15.7 OTHERS 172

16 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 173

16.1 OVERVIEW 174
16.2 DIRECT TENDER 177
16.3 RETAIL SALES 178
16.4 OTHERS 179

17 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY REGION 180

17.1 NORTH AMERICA 181
- 17.1.1 U.S. 194
- 17.1.2 CANADA 202
- 17.1.3 MEXICO 210

18 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 218

18.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 218

19 SWOT ANALYSIS 219

20 COMPANY PROFILE 220

20.1 F. HOFFMANN-LA ROCHE LTD. 220
- 20.1.1 COMPANY SNAPSHOT 220
- 20.1.2 REVENUE ANALYSIS 220
- 20.1.3 COMPANY SHARE ANALYSIS 221
- 20.1.4 PRODUCT PORTFOLIO 221
- 20.1.5 RECENT DEVELOPMENT 221
20.2 KONINLIJKE PHILIPS N.V. 222
- 20.2.1 COMPANY SNAPSHOT 222
- 20.2.2 REVENUE ANALYSIS 222
- 20.2.3 COMPANY SHARE ANALYSIS 223
- 20.2.4 PRODUCT PORTFOLIO 223
- 20.2.5 RECENT DEVELOPMENT 223
20.3 THERMO FISHER SCIENTIFIC INC. 224
- 20.3.1 COMPANY SNAPSHOT 224
- 20.3.2 REVENUE ANALYSIS 224
- 20.3.3 COMPANY SHARE ANALYSIS 225
- 20.3.4 PRODUCT PORTFOLIO 225
- 20.3.5 RECENT DEVELOPMENT 225
20.4 BD 226
- 20.4.1 COMPANY SNAPSHOT 226
- 20.4.2 REVENUE ANALYSIS 226
- 20.4.3 COMPANY SHARE ANALYSIS 227
- 20.4.4 PRODUCT PORTFOLIO 227
- 20.4.5 RECENT DEVELOPMENTS 228
20.5 SIEMENS HEALTHCARE GMBH 229
- 20.5.1 COMPANY SNAPSHOT 229
- 20.5.2 REVENUE ANALYSIS 229
- 20.5.3 COMPANY SHARE ANALYSIS 230
- 20.5.4 PRODUCT PORTFOLIO 230
- 20.5.5 RECENT DEVELOPMENT 230
20.6 AGILENT TECHNOLOGIES, INC. 231
- 20.6.1 COMPANY SNAPSHOT 231
- 20.6.2 REVENUE ANALYSIS 231
- 20.6.3 PRODUCT PORTFOLIO 232
- 20.6.4 RECENT DEVELOPMENTS 232
20.7 ABK BIOMEDICAL INC. 233
- 20.7.1 COMPANY SNAPSHOT 233
- 20.7.2 PRODUCT PORTFOLIO 233
- 20.7.3 RECENT DEVELOPMENT 233
20.8 AB SCIEX PTE LTD. (SUBSIDIARY OF DANAHER.) 234
- 20.8.1 COMPANY SNAPSHOT 234
- 20.8.2 REVENUE ANALYSIS 234
- 20.8.3 PRODUCT PORTFOLIO 235
- 20.8.4 RECENT DEVELOPMENT 235
20.9 ALTOGEN BIOSYSTEMS 236
- 20.9.1 COMPANY SNAPSHOT 236
- 20.9.2 PRODUCT PORTFOLIO 236
- 20.9.3 RECENT DEVELOPMENT 236
20.10 BIOCEPT, INC. 237
- 20.10.1 COMPANY SNAPSHOT 237
- 20.10.2 REVENUE ANALYSIS 237
- 20.10.3 PRODUCT PORTFOLIO 238
- 20.10.4 RECENT DEVELOPMENT 238
20.11 BODITECH MED INC. 239
- 20.11.1 COMPANY SNAPSHOT 239
- 20.11.2 PRODUCT PORTFOLIO 239
- 20.11.3 RECENT DEVELOPMENTS 239
20.12 DIAGNOSTIC BIOSYSTEMS INC. 240
- 20.12.1 COMPANY SNAPSHOT 240
- 20.12.2 PRODUCT PORTFOLIO 240
- 20.12.3 RECENT DEVELOPMENT 240
20.13 DIAZYME LABORATORIES, INC. 241
- 20.13.1 COMPANY SNAPSHOT 241
- 20.13.2 PRODUCT PORTFOLIO 241
- 20.13.3 RECENT DEVELOPMENT 241
20.14 ELABSCIENCE BIOTECHNOLOGY INC. 242
- 20.14.1 COMPANY SNAPSHOT 242
- 20.14.2 PRODUCT PORTFOLIO 242
- 20.14.3 RECENT DEVELOPMENT 242
20.15 EPIGENOMICS AG 243
- 20.15.1 COMPANY SNAPSHOT 243
- 20.15.2 REVENUE ANALYSIS 243
- 20.15.3 PRODUCT PORTFOLIO 244
- 20.15.4 RECENT DEVELOPMENT 244
20.16 FUJIFILM CORPORATION 245
- 20.16.1 COMPANY SNAPSHOT 245
- 20.16.2 REVENUE ANALYSIS 245
- 20.16.3 PRODUCT PORTFOLIO 246
- 20.16.4 RECENT DEVELOPMENT 246
20.17 FUJIREBIO 247
- 20.17.1 COMPANY SNAPSHOT 247
- 20.17.2 PRODUCT PORTFOLIO 247
- 20.17.3 RECENT DEVELOPMENTS 247
20.18 HIPRO BIOTECHNOLOGY CO., LTD. 248
- 20.18.1 COMPANY SNAPSHOT 248
- 20.18.2 PRODUCT PORTFOLIO 248
- 20.18.3 RECENT DEVELOPMENT 248
20.19 ILLUMINA, INC. 249
- 20.19.1 COMPANY SNAPSHOT 249
- 20.19.2 REVENUE ANALYSIS 249
- 20.19.3 PRODUCT PORTFOLIO 250
- 20.19.4 RECENT DEVELOPMENTS 251
20.20 MOLGEN 252
- 20.20.1 COMPANY SNAPSHOT 252
- 20.20.2 PRODUCT PORTFOLIO 252
- 20.20.3 RECENT DEVELOPMENT 252
20.21 QIAGEN 253
- 20.21.1 COMPANY SNAPSHOT 253
- 20.21.2 REVENUE ANALYSIS 253
- 20.21.3 PRODUCT PORTFOLIO 254
- 20.21.4 RECENT DEVELOPMENT 254

20.22 Q-LINE BIOTECH PVT LTD. 255
- 20.22.1 COMPANY SNAPSHOT 255
- 20.22.2 PRODUCT PORTFOLIO 255
- 20.22.3 RECENT DEVELOPMENT 255
20.23 SYSMEX CORPORATION 256
- 20.23.1 COMPANY SNAPSHOT 256
- 20.23.2 REVENUE ANALYSIS 256
- 20.23.3 PRODUCT PORTFOLIO 257
- 20.23.4 RECENT DEVELOPMENT 257
20.24 TEBUBIO 258
- 20.24.1 COMPANY SNAPSHOT 258
- 20.24.2 PRODUCT PORTFOLIO 258
- 20.24.3 RECENT DEVELOPMENT 258
20.25 TOSOH INDIA PVT. LTD. 259
- 20.25.1 COMPANY SNAPSHOT 259
- 20.25.2 PRODUCT PORTFOLIO 259
- 20.25.3 RECENT DEVELOPMENT 259

21 QUESTIONNAIRE 260

22 RELATED REPORTS 264

LIST OF TABLES

TABLE 1 DIFFERENT TYPES OF CANCER NON-INVASIVE SCREENING TESTS FOR DIFFERENT TYPES OF CANCERS 58
TABLE 2 LIVER CANCER RATES 61
TABLE 3 APPROVED DIAGNOSTICS OF LIVER CANCER 62
TABLE 4 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 71
TABLE 5 NORTH AMERICA IMAGING IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 72
TABLE 6 NORTH AMERICA IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 73
TABLE 7 NORTH AMERICA MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 73
TABLE 8 NORTH AMERICA GENETIC TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 75
TABLE 9 NORTH AMERICA BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 76
TABLE 10 NORTH AMERICA BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 76
TABLE 11 NORTH AMERICA OTHERS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 77
TABLE 12 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 81
TABLE 13 NORTH AMERICA STAGE III IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 82
TABLE 14 NORTH AMERICA STAGE II IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 83
TABLE 15 NORTH AMERICA STAGE IV IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 84
TABLE 16 NORTH AMERICA STAGE I IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 85
TABLE 17 NORTH AMERICA STAGE 0 IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 86
TABLE 18 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 90
TABLE 19 NORTH AMERICA SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 91
TABLE 20 NORTH AMERICA RENAL CELL CARCINOMA IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 92
TABLE 21 NORTH AMERICA CLEAR CELL RENAL CELL CARCINOMA IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 93
TABLE 22 NORTH AMERICA CLEAR CELL RENAL CELL CARCINOMA IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 93
TABLE 23 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 98
TABLE 24 NORTH AMERICA PLATFORM BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 99
TABLE 25 NORTH AMERICA PLATFORM BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 99
TABLE 26 NORTH AMERICA INSTRUMENT BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 101
TABLE 27 NORTH AMERICA INSTRUMENT BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 101
TABLE 28 NORTH AMERICA KITS AND REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 102
TABLE 29 NORTH AMERICA KITS AND REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 102
TABLE 30 NORTH AMERICA OTHER CONSUMABLES IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 103
TABLE 31 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 107
TABLE 32 NORTH AMERICA SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 108
TABLE 33 NORTH AMERICA SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 108
TABLE 34 NORTH AMERICA DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 110
TABLE 35 NORTH AMERICA DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 110
TABLE 36 NORTH AMERICA PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 111
TABLE 37 NORTH AMERICA PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 112
TABLE 38 NORTH AMERICA RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 113
TABLE 39 NORTH AMERICA RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 113
TABLE 40 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 118
TABLE 41 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 119
TABLE 42 NORTH AMERICA NEXT GENERATION SEQUENCING IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 120
TABLE 43 NORTH AMERICA FLUORIMMUNOASSAY IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 121
TABLE 44 NORTH AMERICA COMPARATIVE GENOMIC HYBRIDIZATION IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 122
TABLE 45 NORTH AMERICA IMMUNOHISTOCHEMICAL IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 123
TABLE 46 NORTH AMERICA OTHERS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 124
TABLE 47 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION) 128
TABLE 48 NORTH AMERICA MALE IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 129
TABLE 49 NORTH AMERICA FEMALE IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 130
TABLE 50 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 134
TABLE 51 NORTH AMERICA HOSPITALS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 135
TABLE 52 NORTH AMERICA DIAGNOSTIC CENTERS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 136
TABLE 53 NORTH AMERICA CANCER RESEARCH CENTERS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 137
TABLE 54 NORTH AMERICA AMBULATORY SURGICAL CENTERS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 138
TABLE 55 NORTH AMERICA ACADEMIC INSTITUTES IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 139
TABLE 56 NORTH AMERICA OTHERS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 140
TABLE 57 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 144
TABLE 58 NORTH AMERICA DIRECT TENDER IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 145
TABLE 59 NORTH AMERICA RETAIL SALES IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 146
TABLE 60 NORTH AMERICA OTHERS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 147
TABLE 61 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 154
TABLE 62 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 154
TABLE 63 NORTH AMERICA IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 155
TABLE 64 NORTH AMERICA MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 2021-2030 (USD MILLION) 155
TABLE 65 NORTH AMERICA BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 155
TABLE 66 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION) 156
TABLE 67 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 156
TABLE 68 NORTH AMERICA SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 156
TABLE 69 NORTH AMERICA PRIMARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 157
TABLE 70 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 157
TABLE 71 NORTH AMERICA PLATFORM-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 157
TABLE 72 NORTH AMERICA INSTRUMENT-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 158
TABLE 73 NORTH AMERICA KITS & REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 158
TABLE 74 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 158
TABLE 75 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 159
TABLE 76 NORTH AMERICA SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 159
TABLE 77 NORTH AMERICA DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 159
TABLE 78 NORTH AMERICA PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 160
TABLE 79 NORTH AMERICA RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 160
TABLE 80 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION) 160
TABLE 81 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 161
TABLE 82 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 161
TABLE 83 U.S. LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 162
TABLE 84 U.S. IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 162
TABLE 85 U.S. MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 2021-2030 (USD MILLION) 163
TABLE 86 U.S. BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 163
TABLE 87 U.S. LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION) 163
TABLE 88 U.S. LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 164
TABLE 89 U.S. SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 164
TABLE 90 U.S. PRIMARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 164
TABLE 91 U.S. LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 165
TABLE 92 U.S. PLATFORM-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 165
TABLE 93 U.S. INSTRUMENT-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 165
TABLE 94 U.S. KITS & REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 166
TABLE 95 U.S. LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 166
TABLE 96 U.S. LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 166
TABLE 97 U.S. SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 167
TABLE 98 U.S. DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 167
TABLE 99 U.S. PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 167
TABLE 100 U.S. RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 168
TABLE 101 U.S. LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION) 168
TABLE 102 U.S. LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 168
TABLE 103 U.S. LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 169
TABLE 104 CANADA LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 170
TABLE 105 CANADA IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 170
TABLE 106 CANADA MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 2021-2030 (USD MILLION) 170
TABLE 107 CANADA BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 171
TABLE 108 CANADA LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION) 171
TABLE 109 CANADA LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 171
TABLE 110 CANADA SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 172
TABLE 111 CANADA PRIMARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 172
TABLE 112 CANADA LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 172
TABLE 113 CANADA PLATFORM-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 173
TABLE 114 CANADA INSTRUMENT-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 173
TABLE 115 CANADA KITS & REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 173
TABLE 116 CANADA LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 174
TABLE 117 CANADA LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 174
TABLE 118 CANADA SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 175
TABLE 119 CANADA DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 175
TABLE 120 CANADA PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 175
TABLE 121 CANADA RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 176
TABLE 122 CANADA LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION) 176
TABLE 123 CANADA LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 176
TABLE 124 CANADA LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 177
TABLE 125 MEXICO LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 178
TABLE 126 MEXICO IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 178
TABLE 127 MEXICO MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 2021-2030 (USD MILLION) 179
TABLE 128 MEXICO BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 179
TABLE 129 MEXICO LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION) 179
TABLE 130 MEXICO LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 180
TABLE 131 MEXICO SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 180
TABLE 132 MEXICO PRIMARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 180
TABLE 133 MEXICO LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 181
TABLE 134 MEXICO PLATFORM-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 181
TABLE 135 MEXICO INSTRUMENT-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 181
TABLE 136 MEXICO KITS & REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 182
TABLE 137 MEXICO LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 182
TABLE 138 MEXICO LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 182
TABLE 139 MEXICO SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 183
TABLE 140 MEXICO DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 183
TABLE 141 MEXICO PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 183
TABLE 142 MEXICO RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 184
TABLE 143 MEXICO LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION) 184
TABLE 144 MEXICO LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 184
TABLE 145 MEXICO LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 185

LIST OF FIGURES

FIGURE 1 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: SEGMENTATION 28
FIGURE 2 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION 31
FIGURE 3 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: DROC ANALYSIS 32
FIGURE 4 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS 33
FIGURE 5 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS 33
FIGURE 6 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS 34
FIGURE 7 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: MARKET APPLICATION COVERAGE GRID 36
FIGURE 8 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID 38
FIGURE 9 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS 39
FIGURE 10 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: SEGMENTATION 43
FIGURE 11 GROWING AWARENESS OF LIVER CANCER AND INCREASING HEALTHCARE EXPENDITURE ARE EXPECTED TO DRIVE THE GROWTH OF THE NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET FROM 2023 TO 2030 44
FIGURE 12 THE IMAGING TEST SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET IN 2023 & 2030 44
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET 55
FIGURE 14 THE NORTH AMERICA MORTALITY RATE DUE TO CANCER 58
FIGURE 15 INCREASING NORTH AMERICA CANCER RATE IN 2020 59
FIGURE 16 BARRIERS TO EARLY CANCER DIAGNOSIS AND TREATMENT 62
FIGURE 17 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2022 68
FIGURE 18 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION) 69
FIGURE 19 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030) 69
FIGURE 20 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE 70
FIGURE 21 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY CANCER STAGE, 2022 78
FIGURE 22 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY CANCER STAGE, 2023-2030 (USD MILLION) 79
FIGURE 23 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY CANCER STAGE, CAGR (2023-2030) 79
FIGURE 24 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY CANCER STAGE, LIFELINE CURVE 80
FIGURE 25 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2022 87
FIGURE 26 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2023-2030 (USD MILLION) 88
FIGURE 27 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2023-2030) 88
FIGURE 28 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE 89
FIGURE 29 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY PRODUCT, 2022 95
FIGURE 30 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY PRODUCT, 2023-2030 (USD MILLION) 96
FIGURE 31 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY PRODUCT, CAGR (2023-2030) 96
FIGURE 32 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY PRODUCT, LIFELINE CURVE 97
FIGURE 33 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY APPLICATION, 2022 104
FIGURE 34 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY APPLICATION, 2023-2030 (USD MILLION) 105
FIGURE 35 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY APPLICATION, CAGR (2023-2030) 105
FIGURE 36 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY APPLICATION, LIFELINE CURVE 106
FIGURE 37 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, 2022 115
FIGURE 38 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION) 116
FIGURE 39 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, CAGR (2023-2030) 116
FIGURE 40 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, LIFELINE CURVE 117
FIGURE 41 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY GENDER, 2022 125
FIGURE 42 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY GENDER, 2023-2030 (USD MILLION) 126
FIGURE 43 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY GENDER, CAGR (2023-2030) 126
FIGURE 44 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY GENDER, LIFELINE CURVE 127
FIGURE 45 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY END USER, 2022 131
FIGURE 46 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION) 132
FIGURE 47 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030) 132
FIGURE 48 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE 133
FIGURE 49 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022 141
FIGURE 50 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 142
FIGURE 51 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 142
FIGURE 52 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 143
FIGURE 53 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 149
FIGURE 54 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 151
FIGURE 55 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 151
FIGURE 56 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 152
FIGURE 57 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: TEST TYPE (2023-2030) 152
FIGURE 58 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 185